Digestive Disease Department, University Clinic Hospital of Valencia, Valencia, Spain.
University of Valencia, Valencia, Spain.
United European Gastroenterol J. 2019 Oct;7(8):1042-1050. doi: 10.1177/2050640619854277. Epub 2019 May 29.
Knowing patients' ulcerative colitis history is essential to selecting the appropriate therapy according to risk stratification.
To evaluate and identify predictive factors of non-response to aminosalicylates judged as the need for a step-up approach over time.
A case-control study of ulcerative colitis patients treated with aminosalicylates after the diagnosis of disease flare included in the ENEIDA single-centre registry from 1997 to 2017. Long-term treatment maintenance with aminosalicylates and higher therapeutic requirements were recorded. The cumulative incidence of treatment escalation was estimated using Kaplan-Meier curves and compared by the log-rank test. Cox regression analysis was performed to identify predictive factors of treatment with immunomodulators, biological agents or surgery.
A total of 457 patients were included, of whom 28% ( = 126) were non-responders to aminosalicylates. The cumulative probability for a step-up approach within 20 years of follow up was 35%, mainly due to steroid-dependent colitis. Risk factors for treatment escalation were age ≤27 years (hazard ratio 2.31, 95% confidence interval 1.36-3.92), extensive colitis (hazard ratio 1.65, 95% confidence interval 1.04-2.60), Mayo endoscopic subscore ≥2 (hazard ratio 1.45, 95% confidence interval 1.02-2.06) and extraintestinal manifestations (hazard ratio 2.04, 95% confidence interval 1.03-4.05).
Aminosalicylates represent an effective maintenance therapy. Younger age, extensive colitis, endoscopic disease severity and extraintestinal manifestations are risk factors for higher therapeutic requirements.
了解患者的溃疡性结肠炎病史对于根据风险分层选择合适的治疗方法至关重要。
评估和确定氨基水杨酸类药物治疗反应不佳的预测因素,这些因素被判断为随着时间的推移需要逐步升级治疗方法。
对 1997 年至 2017 年期间在 ENEIDA 单中心注册中心登记的诊断为疾病发作后接受氨基水杨酸类药物治疗的溃疡性结肠炎患者进行病例对照研究。记录氨基水杨酸类药物的长期治疗维持情况和更高的治疗需求。使用 Kaplan-Meier 曲线估计治疗升级的累积发生率,并通过对数秩检验进行比较。采用 Cox 回归分析确定免疫调节剂、生物制剂或手术治疗的预测因素。
共纳入 457 例患者,其中 28%(126 例)对氨基水杨酸类药物无反应。在 20 年的随访期间,逐步升级治疗的累积概率为 35%,主要是由于类固醇依赖性结肠炎。治疗升级的危险因素包括年龄≤27 岁(风险比 2.31,95%置信区间 1.36-3.92)、广泛性结肠炎(风险比 1.65,95%置信区间 1.04-2.60)、Mayo 内镜下评分≥2 分(风险比 1.45,95%置信区间 1.02-2.06)和肠外表现(风险比 2.04,95%置信区间 1.03-4.05)。
氨基水杨酸类药物是一种有效的维持治疗方法。年龄较小、广泛性结肠炎、内镜下疾病严重程度和肠外表现是需要更高治疗需求的危险因素。